EUVIMEDEUVIMED entdecken
Crossref

Prevalence of genetically confirmed skeletal muscle channelopathies in the era of next generation sequencing

Vinojini Vivekanandam, Rawan Jaibaji, Richa Sud, Rebecca Ellmers, Iwona Skorupinska, Louise Germaine, Natalie James, Sarah Holmes, Roope Mannikko, Dipa Jayaseelan, Michael G Hanna

Neuromuscular Disorders · 2023

DOI: 10.1016/j.nmd.2023.01.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuromuscular Disorders, 2023. Verfasst von Vinojini Vivekanandam und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Neuromuscular Disorders, UCL QS Institute of Neurology, Queens Square, London WC1N 3BG, United Kingdom. Electronic address: v.vivekanandam…. Hauptthemen laut MEDLINE: Paralysis, Hyperkalemic Periodic, Andersen Syndrome, Myotonic Disorders, Hypokalemic Periodic Paralysis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: Medical Research Council, Department of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We provide an up-to-date and accurate minimum point prevalence of genetically defined skeletal muscle channelopathies which is important for understanding the population impact, planning for treatment needs and future clinical trials. Skeletal muscle channelopathies include myotonia congenita (MC), sodium channel myotonia (SCM), paramyotonia congenita (PMC), hyperkalemic periodic paralysis (hyperPP), hypokalemic periodic paralysis (hypoPP) and Andersen- Tawil Syndrome (ATS). Patients referred to the UK national referral centre for skeletal muscle channelopathies and living in UK were included to calculate the minimum point prevalence using the latest data from the Office for National Statistics population estimate. We calculated a minimum point prevalence of all skeletal muscle channelopathies of 1.99/100 000 (95% CI 1.981-1.999). The minimum point prevalence of MC due to CLCN1 variants is 1.13/100 000 (95% CI 1.123-1.137), SCN4A variants which encode for PMC and SCM is 0.35/100 000 (95% CI 0.346 - 0.354) and for periodic paralysis (HyperPP and HypoPP) 0.41/100 000 (95% CI 0.406-0.414). The minimum point prevalence for ATS is 0.1/100 000 (95% CI 0.098-0.102). There has been an overall increase in point prevalence in skeletal muscle channelopathies compared to previous reports, with the biggest increase found to be in MC. This can be attributed to next generation sequencing and advances in clinical, electrophysiological and genetic characterisation of skeletal muscle channelopathies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Paralysis, Hyperkalemic PeriodicAndersen SyndromeMyotonic DisordersHypokalemic Periodic ParalysisChannelopathiesPrevalenceMuscle, SkeletalHigh-Throughput Nucleotide SequencingHumansNAV1.4 Voltage-Gated Sodium ChannelMyotonia CongenitaMutation

Stichwörter der Autor:innen

Andersen Tawil syndromeChannelopathyMuscle channelopathyMyotonia congenitaPeriodic paralysis

Substanzen

NAV1.4 Voltage-Gated Sodium ChannelSCN4A protein, human

Autor:innen und Institutionen

  • Centre for Neuromuscular Disorders, UCL QS Institute of Neurology, Queens Square, London WC1N 3BG, United Kingdom. Electronic address: v.vivekanandam@ucl.ac.uk.
  • University College London, London, United Kingdom.
  • Centre for Neuromuscular Disorders, UCL QS Institute of Neurology, Queens Square, London WC1N 3BG, United Kingdom.

Förderung

  • Medical Research Council
  • Department of Health

Zitieren

APA

Vivekanandam, V., Jaibaji, R., Sud, R., Ellmers, R., Skorupinska, I., Germaine, L., James, N., Holmes, S., Mannikko, R., Jayaseelan, D., & Hanna, M. G. (2023). Prevalence of genetically confirmed skeletal muscle channelopathies in the era of next generation sequencing. Neuromuscular Disorders. https://doi.org/10.1016/j.nmd.2023.01.007

Vancouver

Vivekanandam V, Jaibaji R, Sud R, Ellmers R, Skorupinska I, Germaine L, et al. Prevalence of genetically confirmed skeletal muscle channelopathies in the era of next generation sequencing. Neuromuscular Disorders. 2023. doi:10.1016/j.nmd.2023.01.007

BibTeX
@article{Vivekanandam2023,
  author = {Vivekanandam, Vinojini and Jaibaji, Rawan and Sud, Richa and Ellmers, Rebecca and Skorupinska, Iwona and Germaine, Louise and James, Natalie and Holmes, Sarah and Mannikko, Roope and Jayaseelan, Dipa and Hanna, Michael G},
  title = {Prevalence of genetically confirmed skeletal muscle channelopathies in the era of next generation sequencing},
  journal = {Neuromuscular Disorders},
  year = {2023},
  doi = {10.1016/j.nmd.2023.01.007}
}
Kostenlos starten →